Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer

摘要: Prostate cancer (PC) is the second most frequent cause of male death in USA. As such, androgen receptor (AR) plays a crucial role PC, making AR major therapeutic target for PC. Current antiandrogen chemotherapy prevents binding to ligand-binding pocket (LBP) AR. However, PC frequently recurs despite treatment and it progresses castration-resistant prostate cancer. Behind this regression renewed signaling initiated via mutations LBP. Hence, there critical need improve options regulate activity sites other than Herein, recently disclosed (2010–2015) allosteric inhibitors are summarized perspective on potential pharmaceutical intervention at these provided.